Neomycin Sulphate Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel (Direct, Indirect), By End Use (Skin Infection, Eye Infection, Ear Infection, Vaccine Production, Veterinary Medicine, Others), By Region & Competition, 2021-2031F

May 2026 | 180 pages | ID: N01BBFB279CCEN
TechSci Research

Abstracts

The global Neomycin Sulphate market is projected to expand significantly, rising from USD 317.19 Million in 2025 to USD 453.77 Million by 2031, exhibiting a compound annual growth rate of 6.15%. Neomycin Sulphate, an aminoglycoside antibiotic derived from Streptomyces fradiae, is widely used in both veterinary and human medicine due to its effectiveness against Gram-negative bacteria. This market's fundamental growth is primarily propelled by the increasing worldwide demand for animal protein, which necessitates stringent disease management strategies to combat enteric infections in livestock and poultry. Concurrently, the pharmaceutical industry contributes to sustained demand through the production of topical medications designed to prevent skin infections in humans. These drivers are fundamental requirements for bacterial control in intensive farming and healthcare, distinguishing them from temporary market fluctuations.

However, despite these robust growth drivers, the market faces a considerable hurdle from the escalating regulatory scrutiny concerning antimicrobial resistance (AMR). Regulatory bodies are progressively curtailing the prophylactic application of vital antibiotics, directly influencing consumption levels. This intensifying regulatory climate is underscored by recent data from the World Organisation for Animal Health, which reported a 5% decline in global antimicrobial use in animals between 2020 and 2022, highlighting the increasing effect of stewardship initiatives on the industry. These stringent regulations oblige manufacturers to operate within intricate compliance frameworks, potentially hindering the growth in sales volume for neomycin sulphate within crucial agricultural sectors.

Market Driver

The growth of the global veterinary healthcare sector serves as a significant impetus for market expansion, especially driven by the increased application of medicated feed additives to manage enteric pathogens in poultry and swine. As livestock producers expand operations to satisfy growing demand for animal protein, their dependence on aminoglycosides such as neomycin sulphate has intensified for maintaining herd health and preventing bacterial outbreaks. Recent consumption data confirms this trend, showing a resurgence in usage despite existing regulatory challenges. For instance, the U.S. FDA's December 2025 '2024 Summary Report' revealed a 16% increase in domestic sales of medically important antimicrobials for food-producing animals in 2024 compared to the previous year. This substantial volume growth highlights the market's ongoing reliance on efficacious antibiotic treatments. Moreover, Phibro Animal Health Corporation reported an 81% surge in net sales for its Medicated Feed Additives segment during the first fiscal quarter of 2025, indicating strong commercial dynamism and market consolidation within the animal health sector.

Concurrently, the market is experiencing significant momentum from the escalating demand for topical dermatological preparations, with neomycin remaining a crucial active ingredient for addressing bacterial skin infections and averting post-surgical complications. Pharmaceutical firms observe consistent sales of antibiotic creams and ointments, propelled by greater consumer understanding of wound care and an increasing occurrence of minor skin abrasions needing preventative treatment. This demand is reflected in the recent financial outcomes of leading consumer health companies. Haleon plc's 'Full Year Results 2024', published in February 2025, indicated high-single-digit organic revenue growth within its Skin Health category, largely attributable to the robust performance of its topical antibiotic brands. The expansion of this segment underscores the vital contribution of human-use topical antibiotics to the overall neomycin sulphate market, supplementing the volume demand originating from the veterinary domain.

Market Challenge

The intensifying regulatory environment surrounding antimicrobial resistance (AMR) presents a significant constraint on the volume expansion potential of the global Neomycin Sulphate market. Regulatory authorities and agricultural alliances are rigorously implementing stewardship policies that restrict the prophylactic use of critically important antibiotics, a practice that traditionally constituted a large share of neomycin consumption within the veterinary sector. This fundamental shift, moving from widespread disease prevention to more focused therapeutic applications, inherently reduces the available market. Consequently, as producers adopt alternative health management approaches to adhere to these strict regulations, the foundational demand for neomycin sulphate in livestock feed and water additives faces a lasting reduction, thereby directly hindering overall market growth.

The effect of these stewardship policies on consumption volumes is clearly demonstrated by current industry statistics. The British Poultry Council reported in 2025 that the UK poultry meat industry has sustained a complete absence of preventative antibiotic use and has collectively reduced total antibiotic usage by more than 83% since 2012. These statistics exemplify how effective adherence to AMR regulations effectively limits the potential for increased sales volumes, compelling manufacturers to operate within a market characterized by restricted demand.

Market Trends

The wound care sector is undergoing rapid transformation with the incorporation of neomycin sulphate into sophisticated hydrogel and biofilm dressing systems, especially for managing chronic diabetic foot ulcers and severe burn injuries. Manufacturers are innovating beyond conventional hydrophobic ointments, which typically exhibit limited penetration, by developing moisture-retentive hydrogels that provide sustained, localized antibiotic release and effectively disrupt bacterial biofilms. This technological progression directly addresses the urgent requirement for efficient infection control in intricate, non-healing wounds where systemic antibiotics prove inadequate. The commercial viability of these advanced formulations is confirmed by recent corporate results. Smith+Nephew's 'Third Quarter 2025 Trading Report' from November 2025 highlighted a 6.0% underlying revenue growth for its Advanced Wound Management unit, predominantly driven by double-digit expansion in its Advanced Wound Bioactives portfolio, thus affirming the market's decisive shift towards high-technology therapeutic dressings.

Concurrently, the market is witnessing a fundamental shift towards specialized otic and dermatological products for companion animals, moving away from its traditional dependence on livestock farming. Veterinary pharmaceutical firms are increasingly broadening their product offerings to leverage the burgeoning 'pet humanization' trend, focusing on developing specific neomycin-based treatments for skin infections in dogs and cats instead of lower-margin feed additives. This strategic realignment is fueled by pet owners' heightened propensity to invest in superior healthcare solutions for dermatological issues. The substantial growth of this sector is supported by financial disclosures from industry leaders. Zoetis Inc.'s 'Third Quarter 2025 Results' from November 2025 reported an 8% increase in revenue for its international companion animal products, largely propelled by sustained demand within its dermatology portfolio, thereby emphasizing the profitable prospects of infection control products within the pet care industry.

Key Market Players

• Pfizer Limited
• Shandong Qilu King-Phar Pharmaceutical Co., Ltd.
• Myland Pharma Pvt Ltd
• Xi'an International Healthcare Factory Co., Ltd.
• Shandong Yifan Chemical Technology Co., Ltd.
• Xi'an Henrikang Biotech Co., Ltd.
• Hebei Shengxue Dacheng Pharmaceutical Co., Ltd.
• Jinyao Xinrui Pharmaceutical Co. Ltd
• Xinyu Pharmaceutical Co. Ltrd
• Humanwell Healthcare (Group) Co., Ltd

Report Scope

In this report, the Global Neomycin Sulphate Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Neomycin Sulphate Market, By Sales Channel
• Direct
• Indirect
• Neomycin Sulphate Market, By End Use
• Skin Infection
• Eye Infection
• Ear Infection
• Vaccine Production
• Veterinary Medicine
• Others
• Neomycin Sulphate Market, By Region
• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neomycin Sulphate Market.

Available Customizations:

Global Neomycin Sulphate Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL NEOMYCIN SULPHATE MARKET OUTLOOK

5.1. Market Size & Forecast
  5.1.1. By Value
5.2. Market Share & Forecast
  5.2.1. By Sales Channel (Direct, Indirect)
  5.2.2. By End Use (Skin Infection, Eye Infection, Ear Infection, Vaccine Production, Veterinary Medicine, Others)
  5.2.3. By Region
  5.2.4. By Company (2025)
5.3. Market Map

6. NORTH AMERICA NEOMYCIN SULPHATE MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Sales Channel
  6.2.2. By End Use
  6.2.3. By Country
6.3. North America: Country Analysis
  6.3.1. United States Neomycin Sulphate Market Outlook
    6.3.1.1. Market Size & Forecast
      6.3.1.1.1. By Value
    6.3.1.2. Market Share & Forecast
      6.3.1.2.1. By Sales Channel
      6.3.1.2.2. By End Use
  6.3.2. Canada Neomycin Sulphate Market Outlook
    6.3.2.1. Market Size & Forecast
      6.3.2.1.1. By Value
    6.3.2.2. Market Share & Forecast
      6.3.2.2.1. By Sales Channel
      6.3.2.2.2. By End Use
  6.3.3. Mexico Neomycin Sulphate Market Outlook
    6.3.3.1. Market Size & Forecast
      6.3.3.1.1. By Value
    6.3.3.2. Market Share & Forecast
      6.3.3.2.1. By Sales Channel
      6.3.3.2.2. By End Use

7. EUROPE NEOMYCIN SULPHATE MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Sales Channel
  7.2.2. By End Use
  7.2.3. By Country
7.3. Europe: Country Analysis
  7.3.1. Germany Neomycin Sulphate Market Outlook
    7.3.1.1. Market Size & Forecast
      7.3.1.1.1. By Value
    7.3.1.2. Market Share & Forecast
      7.3.1.2.1. By Sales Channel
      7.3.1.2.2. By End Use
  7.3.2. France Neomycin Sulphate Market Outlook
    7.3.2.1. Market Size & Forecast
      7.3.2.1.1. By Value
    7.3.2.2. Market Share & Forecast
      7.3.2.2.1. By Sales Channel
      7.3.2.2.2. By End Use
  7.3.3. United Kingdom Neomycin Sulphate Market Outlook
    7.3.3.1. Market Size & Forecast
      7.3.3.1.1. By Value
    7.3.3.2. Market Share & Forecast
      7.3.3.2.1. By Sales Channel
      7.3.3.2.2. By End Use
  7.3.4. Italy Neomycin Sulphate Market Outlook
    7.3.4.1. Market Size & Forecast
      7.3.4.1.1. By Value
    7.3.4.2. Market Share & Forecast
      7.3.4.2.1. By Sales Channel
      7.3.4.2.2. By End Use
  7.3.5. Spain Neomycin Sulphate Market Outlook
    7.3.5.1. Market Size & Forecast
      7.3.5.1.1. By Value
    7.3.5.2. Market Share & Forecast
      7.3.5.2.1. By Sales Channel
      7.3.5.2.2. By End Use

8. ASIA PACIFIC NEOMYCIN SULPHATE MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Sales Channel
  8.2.2. By End Use
  8.2.3. By Country
8.3. Asia Pacific: Country Analysis
  8.3.1. China Neomycin Sulphate Market Outlook
    8.3.1.1. Market Size & Forecast
      8.3.1.1.1. By Value
    8.3.1.2. Market Share & Forecast
      8.3.1.2.1. By Sales Channel
      8.3.1.2.2. By End Use
  8.3.2. India Neomycin Sulphate Market Outlook
    8.3.2.1. Market Size & Forecast
      8.3.2.1.1. By Value
    8.3.2.2. Market Share & Forecast
      8.3.2.2.1. By Sales Channel
      8.3.2.2.2. By End Use
  8.3.3. Japan Neomycin Sulphate Market Outlook
    8.3.3.1. Market Size & Forecast
      8.3.3.1.1. By Value
    8.3.3.2. Market Share & Forecast
      8.3.3.2.1. By Sales Channel
      8.3.3.2.2. By End Use
  8.3.4. South Korea Neomycin Sulphate Market Outlook
    8.3.4.1. Market Size & Forecast
      8.3.4.1.1. By Value
    8.3.4.2. Market Share & Forecast
      8.3.4.2.1. By Sales Channel
      8.3.4.2.2. By End Use
  8.3.5. Australia Neomycin Sulphate Market Outlook
    8.3.5.1. Market Size & Forecast
      8.3.5.1.1. By Value
    8.3.5.2. Market Share & Forecast
      8.3.5.2.1. By Sales Channel
      8.3.5.2.2. By End Use

9. MIDDLE EAST & AFRICA NEOMYCIN SULPHATE MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Sales Channel
  9.2.2. By End Use
  9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
  9.3.1. Saudi Arabia Neomycin Sulphate Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Sales Channel
      9.3.1.2.2. By End Use
  9.3.2. UAE Neomycin Sulphate Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Sales Channel
      9.3.2.2.2. By End Use
  9.3.3. South Africa Neomycin Sulphate Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Sales Channel
      9.3.3.2.2. By End Use

10. SOUTH AMERICA NEOMYCIN SULPHATE MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Sales Channel
  10.2.2. By End Use
  10.2.3. By Country
10.3. South America: Country Analysis
  10.3.1. Brazil Neomycin Sulphate Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Sales Channel
      10.3.1.2.2. By End Use
  10.3.2. Colombia Neomycin Sulphate Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Sales Channel
      10.3.2.2.2. By End Use
  10.3.3. Argentina Neomycin Sulphate Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Sales Channel
      10.3.3.2.2. By End Use

11. MARKET DYNAMICS

11.1. Drivers
11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. GLOBAL NEOMYCIN SULPHATE MARKET: SWOT ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. COMPETITIVE LANDSCAPE

15.1. Pfizer Limited
  15.1.1. Business Overview
  15.1.2. Products & Services
  15.1.3. Recent Developments
  15.1.4. Key Personnel
  15.1.5. SWOT Analysis
15.2. Shandong Qilu King-Phar Pharmaceutical Co., Ltd.
15.3. Myland Pharma Pvt Ltd
15.4. Xi'an International Healthcare Factory Co., Ltd.
15.5. Shandong Yifan Chemical Technology Co., Ltd.
15.6. Xi'an Henrikang Biotech Co., Ltd.
15.7. Hebei Shengxue Dacheng Pharmaceutical Co., Ltd.
15.8. Jinyao Xinrui Pharmaceutical Co. Ltd
15.9. Xinyu Pharmaceutical Co. Ltrd
15.10. Humanwell Healthcare (Group) Co., Ltd

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER